Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Mersana Therapeutics Inc (MRSN)

Mersana Therapeutics Inc (MRSN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Lags Revenue Estimates

Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -1,933.33% and 85.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for...

MRSN : 6.50 (-0.46%)
ALIM : 3.43 (-10.42%)
Seattle Genetics (SGEN) Reports Q3 Loss, Tops Revenue Estimates

Seattle Genetics (SGEN) delivered earnings and revenue surprises of -11.96% and 8.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

SGEN : 121.22 (-1.80%)
MRSN : 6.50 (-0.46%)
Are Medical Stocks Lagging Aerie Pharmaceuticals (AERI) This Year?

Here is how Aerie Pharmaceuticals (AERI) and Mersana Therapeutics, Inc. (MRSN) have performed compared to their sector so far this year.

AERI : 15.25 (+0.07%)
MRSN : 6.50 (-0.46%)
Mersana Therapeutics, Inc. (MRSN) Just Flashed Golden Cross Signal: Do You Buy?

Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?

MRSN : 6.50 (-0.46%)
The Zacks Analyst Blog Highlights Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex Pharmaceuticals

Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.

GSK : 33.76 (-0.68%)
AMGN : 282.62 (-0.39%)
VRTX : 315.30 (+0.74%)
CCXI : 51.99 (+0.06%)
MRSN : 6.50 (-0.46%)
Biotech Stock Roundup: AMGN's Q2 Earnings, CCXI Acquisition & More Updates

Earnings updates from Amgen (AMGN) and its ChemoCentryx (CCXI) acquisition are a few key highlights from the biotech sector during the past week.

GSK : 33.76 (-0.68%)
AMGN : 282.62 (-0.39%)
VRTX : 315.30 (+0.74%)
CCXI : 51.99 (+0.06%)
MRSN : 6.50 (-0.46%)
Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Tops Revenue Estimates

Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -10% and 34.72%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?...

MRSN : 6.50 (-0.46%)
MNKD : 4.41 (-2.22%)
Mersana Therapeutics Provides Business Update and Announces Second Quarter 2022 Financial Results

Approaching full enrollment in UPLIFT clinical trial; initiated patient screening in UP-NEXT clinical trialCleared INDs for XMT-1660 and XMT-2056Enhanced...

MRSN : 6.50 (-0.46%)
Mersana Therapeutics Announces Option Agreement with GSK for the Co-Development and Commercialization of XMT-2056, an Immunosynthen ADC Targeting HER2

GSK receives exclusive global license option for XMT-2056 Mersana to receive $100 million upfront option purchase feeIf GSK exercises its option, Mersana...

MRSN : 6.50 (-0.46%)
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on...

MRSN : 6.50 (-0.46%)

Barchart Exclusives

Trading Pressure Can Impact a Trader's Performance
Trading pressure has been going on for so long that we feel there is no way to eliminate it, but we can successfully react to it in many ways. We, as traders, tend to put ourselves in pressure situations frequently. I want to help you recognize these potential pressure situations and prepare you well ahead when they occur. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar